Vical Incorporated (San Diego, CA, www.vical.com) has introduced a cell-free manufacturing process designed to produce large quantities of vaccine in a matter of days, compared with the several months required for conventional vaccine production.
Vical Incorporated (San Diego, CA, www.vical.com) has introduced a cell-free manufacturing process designed to produce large quantities of vaccine in a matter of days, compared with the several months required for conventional vaccine production. The RapidResponse DNA platform is intended to significantly reduce the time required to develop, manufacture, and deploy vaccines against emerging diseases during the early stages of an infectious outbreak. The company believes that the RapidResponse DNA platform can overcome the time, capacity, and cost challenges of manufacturing conventional vaccines, which use killed or disabled viruses grown in chicken eggs or via cell culture, requiring months of production time in large facilities. Vical has also been awarded a three-year, $6 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for further development of this manufacturing process.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.